Weight changes after adjuvant treatment in Korean women with early breast cancer

Han, Hye Sung; Lee, Moon Hyoung; Kim, Jee Hyun; Kim, Sung Won; Kim, In Ah; Oh, Do Youn; Im, Seock Ah; Bang, Soo Mee; Lee, Jong Seok

doi:10.1007/s10549-008-9984-6

Cited by 46 publications

(67 citation statements)

References 32 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapy has been associated with weight gain among breast cancer survivors in some [14–16, 21, 39, 40] but not in all studies [22, 28, 32, 41]. A significant association was not observed between chemotherapy and weight gain following a breast cancer diagnosis after adjustment for other factors.…”

Section: Discussionmentioning

confidence: 96%

Weight gain prior to entry into a weight-loss intervention study among overweight and obese breast cancer survivors

et al. 2014

View full text Add to dashboard Cite

Purpose Changes in cancer therapy, in addition to changes in obesity prevalence, suggest the need for a current assessment of weight gain patterns following breast cancer diagnosis. The aim of this study was to evaluate factors associated with weight gain among breast cancer survivors prior to enrolling into a behavioral weight loss intervention. Methods Anthropometric measures and data on weight-related factors were collected at baseline on 665 breast cancer survivors. Postdiagnosis weight gain was determined between entry into the trial and previous diagnosis up to 5 years. Multivariate logistic regression analyses were used to evaluate the association between weight gain and influencing factors. Results The mean weight gain was 4.5 % body weight (standard deviation=10.6); 44 % of women experienced ≥5 % body weight gain. The risk of weight gain was inversely associated with age (adjusted odds ratio (ORadj)=0.97, 95 % confidence interval (95 % CI) 0.95–0.99), Hispanic ethnicity (ORadj=0.30, 95 % CI 0.13–0.68), and overweight (ORadj= 0.11, 95 % CI 0.05–0.23) or obese (ORadj=0.03, 95 % CI 0.02–0.07) status at diagnosis and positively associated with time elapsed since diagnosis (ORadj=1.19/year, 95 % CI 1.04–1.36). Women prescribed aromatase inhibitors were 46 % less likely to gain weight compared to women prescribed selective estrogen-receptor modulators (ORadj=0.54, 95 % CI 0.31–0.93). The risk of weight gain was positively associated with smoking at diagnosis (ORadj=2.69, 95 % CI 1.12–6.49) although this was attributable to women who subsequently quit smoking. Conclusions Postdiagnosis weight gain is common and complex and influenced by age, ethnicity, weight, smoking status, time elapsed since diagnosis, and endocrine-modulating therapy. Implications for cancer survivors Weight gain continues to be a concern following a diagnosis of breast cancer. Factors influencing this weight gain include age, ethnicity, weight, smoking status, time elapsed since diagnosis, and endocrine-modulating therapy. Effective weight management strategies are needed for this population of women.

show abstract

Section: Discussionmentioning

confidence: 96%

Weight gain prior to entry into a weight-loss intervention study among overweight and obese breast cancer survivors

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Weight gain reported as a symptom or bothersome symptom in Year One ranged from 18 to 52 % [40,51] and in Year Five from 7 to 55 percent [35,37]. Most studies did not provide specific amounts of weight change; however, in the few studies that did provide specific amounts, mean weight change reported in Year One ranged from -0.01 to 1.8 kg [56,66]. Some studies reported the proportion of women who lost weight during the first two years and the proportion whose weight was stable, in addition to the proportion who gained weight [32,38].…”

Section: Discussionmentioning

confidence: 99%

“…One study reported significantly greater effect sizes for weight gain in the ET group as compared to no ET at 6, 12, and 18 months from breast cancer diagnosis (p \ 0.01) [55], while another study reported significantly less weight loss at Year One in the ET as compared to the no-ET group (p = 0.007) [56].…”

Section: Unspecified Etmentioning

confidence: 99%

Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?

Nyrop

Muss

et al. 2016

Breast Cancer Res Treat

View full text Add to dashboard Cite

Most breast cancer (BC) tumors are early stage and hormone receptor positive, where treatment generally includes adjuvant endocrine treatment (ET). Oncology providers and women about to start ET want to know about side effects, including potential weight gain. The aim of this study was a literature review to identify the independent effect of ET on post-diagnosis weight gain. Weight gain is of concern with regard to potential associations with BC recurrence, mortality, and quality of life in survivorship. We conducted a targeted review of the literature. Thirty-eight studies met our inclusion criteria. Patient-reported weight gain ranged widely from 18 to 52 % of patients in Year 1 and from 7 to 55 % in Year 5. Some studies reported categories of weight change: lost weight (9-17 %), stable weight (47-64 %), and gained weight (27-36 %). Most studies comparing ET with placebo or tamoxifen with AI reported no significant difference between the two groups. Wide-ranging and inconsistent results point to the need for further research to clarify annual weight change (loss, gain, stability) from BC diagnosis through 5 years of ET and beyond. There is also a need to explore weight change by type of ET and to explore risk factors for weight gain in women on ET, including tumor type, sociodemographic characteristics, and health behaviors. More specific information is needed to identify high-risk BC patients who could be targeted for weight management interventions.

show abstract

“…It is important to know that all studies showing evidence of significant weight gain following adjuvant treatment were reported from the United States and Western European countries. Such evidence has not been observed in Korean women with early BC suggesting that some other ethnic, biologic or genetic factors which might play a role [24].…”

Section: Introductionmentioning

confidence: 89%

Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey

et al. 2010

View full text Add to dashboard Cite

Weight gain is a well-known and unwanted complication of adjuvant chemotherapy in breast cancer. We observed that the female Turkish cancer patients frequently gain weight with adjuvant treatment of breast cancer and planned to examine the magnitude of this problem in early breast cancer patients treated at our hospital. A total of 176 early breast cancer patients who received their adjuvant systemic therapy in Marmara University Hospital between 2003 and 2007 are included in the study. We recorded their weight before and after chemotherapy and also a year after chemotherapy to find out whether the change with weight is transitory. We have also recorded demographic information, including the educational level, menopausal status, the type of chemotherapy or hormonal treatment administered stage of disease, marital status, occupation and the underlying diseases to analyze the relationship between change in weight and these parameters. Median age of patients was 53 and 72% of patients were postmenopausal. Educational level was equally distributed for primary education (27%), high school (40%), and university (33%). The majority of the patients (76%) was married, had two children (69%) and was housewife (60%). Family history of any cancer was high (32%). Most of the patients had stage II cancer (56%), received anthracyclines+/- taxane based chemotherapy (98%) and had no underlying disease (68%). The majority also did not smoke (73%) or drink alcohol (93%). A total of 67% and 72% patients gained weight upon completion and one year after completion of chemotherapy. Mean weight before the chemotherapy, upon completion of chemotherapy and one year after completion of chemotherapy were 68.9 kg, 70.6 kg (P = 0.000) and 71.9 kg (P = 0.000) respectively. Mean body mass index was 27.1 at baseline, 27.8 upon completion of chemotherapy (P = 0.000) and 28.3 one year after completion of chemotherapy (P = 0.000). Age, menopausal status, multiparity and presence of comorbid diseases had statistically significant impact on weight gain following adjuvant therapy in breast cancer patients (P = 0.000, P = 0.008, P = 0.015 and P = 0.017 respectively). This study shows that Turkish women with early breast cancer gain weight after adjuvant systemic therapy, in line with European and American counterparts. This increase in weight is maintained at least one year after adjuvant therapy. Given the adverse consequences of weight gain in terms of both breast cancer prognosis and general health, it is necessary to inform patients about this change and to develop strategies for weight maintenance during and after systemic therapy.

show abstract

Weight changes after adjuvant treatment in Korean women with early breast cancer

Abstract: This study shows that Korean women with early breast cancer do not gain weight after adjuvant treatment. Further studies are needed to determine differences between Asian and Western women in terms of weight changes and prognosis in early breast cancer.

Cited by 46 publications

References 32 publications

Weight gain prior to entry into a weight-loss intervention study among overweight and obese breast cancer survivors

Weight gain prior to entry into a weight-loss intervention study among overweight and obese breast cancer survivors

Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?

Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey

Contact Info

Product

Resources

About